Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To ... MarketWatch (press release) Ltd. (hereafter, Daiichi Sankyo; TSE 4568) announced today the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan. Under the terms of the agreement, ... |
